221 related articles for article (PubMed ID: 23113766)
1. Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40.
Pratico ED; Sullenger BA; Nair SK
Nucleic Acid Ther; 2013 Feb; 23(1):35-43. PubMed ID: 23113766
[TBL] [Abstract][Full Text] [Related]
2. OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology.
Ishii N; Takahashi T; Soroosh P; Sugamura K
Adv Immunol; 2010; 105():63-98. PubMed ID: 20510730
[TBL] [Abstract][Full Text] [Related]
3. Frontline Science: OX40 agonistic antibody reverses immune suppression and improves survival in sepsis.
Unsinger J; Walton AH; Blood T; Tenney DJ; Quigley M; Drewry AM; Hotchkiss RS
J Leukoc Biol; 2021 Apr; 109(4):697-708. PubMed ID: 33264454
[TBL] [Abstract][Full Text] [Related]
4. Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells.
Kondo K; Okuma K; Tanaka R; Zhang LF; Kodama A; Takahashi Y; Yamamoto N; Ansari AA; Tanaka Y
Hum Immunol; 2007 Jul; 68(7):563-71. PubMed ID: 17584577
[TBL] [Abstract][Full Text] [Related]
5. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer.
Redmond WL; Weinberg AD
Crit Rev Immunol; 2007; 27(5):415-36. PubMed ID: 18197805
[TBL] [Abstract][Full Text] [Related]
6. OX40 Stimulation Enhances Protective Immune Responses Induced After Vaccination With Attenuated Malaria Parasites.
Othman AS; Franke-Fayard BM; Imai T; van der Gracht ETI; Redeker A; Salman AM; Marin-Mogollon C; Ramesar J; Chevalley-Maurel S; Janse CJ; Arens R; Khan SM
Front Cell Infect Microbiol; 2018; 8():247. PubMed ID: 30073152
[TBL] [Abstract][Full Text] [Related]
7. OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection.
Jacobi FJ; Wild K; Smits M; Zoldan K; Csernalabics B; Flecken T; Lang J; Ehrenmann P; Emmerich F; Hofmann M; Thimme R; Neumann-Haefelin C; Boettler T
J Hepatol; 2019 Jun; 70(6):1103-1113. PubMed ID: 30826436
[TBL] [Abstract][Full Text] [Related]
8. OX40/OX40L costimulation affects induction of Foxp3+ regulatory T cells in part by expanding memory T cells in vivo.
Xiao X; Kroemer A; Gao W; Ishii N; Demirci G; Li XC
J Immunol; 2008 Sep; 181(5):3193-201. PubMed ID: 18713990
[TBL] [Abstract][Full Text] [Related]
9. OX40 complexes with phosphoinositide 3-kinase and protein kinase B (PKB) to augment TCR-dependent PKB signaling.
So T; Choi H; Croft M
J Immunol; 2011 Mar; 186(6):3547-55. PubMed ID: 21289304
[TBL] [Abstract][Full Text] [Related]
10. OX40-mediated differentiation to effector function requires IL-2 receptor signaling but not CD28, CD40, IL-12Rbeta2, or T-bet.
Williams CA; Murray SE; Weinberg AD; Parker DC
J Immunol; 2007 Jun; 178(12):7694-702. PubMed ID: 17548606
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction.
Song Y; Margolles-Clark E; Bayer A; Buchwald P
Br J Pharmacol; 2014 Nov; 171(21):4955-69. PubMed ID: 24930776
[TBL] [Abstract][Full Text] [Related]
12. OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory viruses.
Goulding J; Tahiliani V; Salek-Ardakani S
Immunol Rev; 2011 Nov; 244(1):149-68. PubMed ID: 22017437
[TBL] [Abstract][Full Text] [Related]
13. Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Oberst MD; Augé C; Morris C; Kentner S; Mulgrew K; McGlinchey K; Hair J; Hanabuchi S; Du Q; Damschroder M; Feng H; Eck S; Buss N; de Haan L; Pierce AJ; Park H; Sylwester A; Axthelm MK; Picker L; Morris NP; Weinberg A; Hammond SA
Mol Cancer Ther; 2018 May; 17(5):1024-1038. PubMed ID: 29545330
[TBL] [Abstract][Full Text] [Related]
14. OX40 ligation of CD4+ T cells enhances virus-specific CD8+ T cell memory responses independently of IL-2 and CD4+ T regulatory cell inhibition.
Yu Q; Yue FY; Gu XX; Schwartz H; Kovacs CM; Ostrowski MA
J Immunol; 2006 Feb; 176(4):2486-95. PubMed ID: 16456009
[TBL] [Abstract][Full Text] [Related]
15. Characterization of rat OX40 ligand by monoclonal antibody.
Satake Y; Akiba H; Takeda K; Atsuta M; Yagita H; Okumura K
Biochem Biophys Res Commun; 2000 Apr; 270(3):1041-8. PubMed ID: 10772947
[TBL] [Abstract][Full Text] [Related]
16. Science gone translational: the OX40 agonist story.
Weinberg AD; Morris NP; Kovacsovics-Bankowski M; Urba WJ; Curti BD
Immunol Rev; 2011 Nov; 244(1):218-31. PubMed ID: 22017441
[TBL] [Abstract][Full Text] [Related]
17. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling.
Hombach AA; Abken H
Int J Cancer; 2011 Dec; 129(12):2935-44. PubMed ID: 22030616
[TBL] [Abstract][Full Text] [Related]
18. The role of OX40-mediated co-stimulation in T-cell activation and survival.
Redmond WL; Ruby CE; Weinberg AD
Crit Rev Immunol; 2009; 29(3):187-201. PubMed ID: 19538134
[TBL] [Abstract][Full Text] [Related]
19. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
[TBL] [Abstract][Full Text] [Related]
20. In vivo antitumor function of tumor antigen-specific CTLs generated in the presence of OX40 co-stimulation in vitro.
Pham Minh N; Murata S; Kitamura N; Ueki T; Kojima M; Miyake T; Takebayashi K; Kodama H; Mekata E; Tani M
Int J Cancer; 2018 Jun; 142(11):2335-2343. PubMed ID: 29313971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
